Cowen And Company, LLC Cassava Sciences Inc Transaction History

Cowen And Company, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	BUY	$12.64 - $30.11 $6.32 Million - $15.1 Million	500,000 New	500,000 $11.3 Million
Q3 2022 Nov 14, 2022	BUY	$16.33 - $51.06 $317,896 - $993,985	19,467 New	19,467 $187,000
Q1 2022 May 16, 2022	SELL	$32.6 - $53.05 $414,020 - $673,735	-12,700 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$36.77 - $90.91 $5.97 Million - $14.8 Million	-162,300 Reduced 92.74%	12,700 $555,000
Q3 2021 Nov 12, 2021	BUY	$41.79 - $135.3 $7.31 Million - $23.7 Million	175,000 New	175,000 $10.9 Million

207

14M

2.98M

6.57M

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $94.2M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

Get notified when there are updates to the investment portfolio of Cowen And Company, LLC, based on Form 13F filings with the SEC.

Stay updated on Cowen And Company, LLC with notifications on news.